Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers

AIM: Selisistat (SEN0014196), a first-in-class SirT1 inhibitor, is being developed as a disease-modifying therapy for Huntington's disease. This first-in-human study investigated the safety, pharmacokinetics and pharmacogenomics of single and multiple doses of selisistat in healthy male and fem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Westerberg, Goran, Chiesa, Joseph A, Andersen, Claus A, Diamanti, Daniela, Magnoni, Letizia, Pollio, Giuseppe, Darpo, Borje, Zhou, Meijian
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2015
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4345958/
https://ncbi.nlm.nih.gov/pubmed/25223836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12513
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados